Autonomix medical, inc. treats first patient in follow-on market expansion phase (“poc 2”) of proof-of-concept human clinical study

Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain poc 2 phase builds on early success and positive results demonstrated in poc 1 in patients with severe pancreatic cancer pain, supporting multi-indication growth strategy the woodlands, tx, june 30, 2025 (globe newswire) -- autonomix medical, inc. (nasdaq: amix) (“autonomix” or the “company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the first patient has been enrolled and treated in the follow-on phase to its proof-of-concept human clinical trial (“poc 2”) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate cancer pain. “we're executing on a bold vision to expand the reach of our technology beyond pancreatic cancer pain and into a broader range of high-need visceral cancer indications,” said brad hauser, ceo of autonomix.
AMIX Ratings Summary
AMIX Quant Ranking